- 著者
 
          - 
             
             Roland Richard Tilz
             
             Roza Meyer-Saraei
             
             Charlotte Eitel
             
             Thomas Fink
             
             Vanessa Sciacca
             
             Lisbeth Delgado Lopez
             
             Bettina Kirstein
             
             Michael Schlüter
             
             Julia Vogler
             
             Karl-Heinz Kuck
             
             Christian-H. Heeger
             
          
 
          
          
          - 出版者
 
          - The Japanese Circulation Society
 
          
          
          - 雑誌
 
          - Circulation Journal (ISSN:13469843)
 
          
          
          - 巻号頁・発行日
 
          - pp.CJ-21-0094,  (Released:2021-04-13)
 
          
          
          - 参考文献数
 
          - 18
 
          
          
          - 被引用文献数
 
          - 
             
             
             28
             
             
          
        
 
        
        
        Background:The arctic front cryoballoon (AF-CB) provides effective and durable pulmonary vein isolation (PVI) associated with encouraging clinical outcome. The POLARx cryoballoon incorporates unique features and design changes that may translate into improved efficacy, safety and further simplified balloon-based procedures. Efficacy and safety of the novel POLARx cryoballoon was compared to the fourth generation AF-CB (AF-CB4).Methods and Results:Twenty-five consecutive patients with paroxysmal or persistent atrial fibrillation were prospectively enrolled, underwent POLARx-based PVI (POLARx group) and were compared to 25 consecutive patients treated with the AF-CB4 (AF-CB4 group). All PVs were successfully isolated utilizing the POLARx and AF-CB4. A significant difference regarding the mean minimal cryoballoon temperatures reached using the AF-CB4 and POLARx (−50±6℃ vs. −57±7℃, P=0.004) was observed. Real-time PVI was visualized in 81% of POLARx patients and 42% of AF-CB4 patients (P<0.001). Utilizing the POLARx, a trend towards shorter median procedure time (POLARx: 45 [39, 53] min vs. AF-CB4: 55 [50, 60] min; P=0.062) was found. No differences were observed between AF-CB4 and POLARx concerning catheter maneuverability, catheter stability and periprocedural complications.Conclusions:The novel POLARx showed similar safety and efficacy compared to the AF-CB4. A higher rate of real-time PV recordings and significantly lower minimal balloon temperatures were observed using the POLARx.